Search

Meeting Coverage:

Association for Research in Vision & Ophthalmology

ARVO: 2025

Surgical Pearls for Sickle Cell Retinopathy

Jennifer I. Lim, MD

Show Description +

Dr. Lim explores the benefits of surgical intervention for proliferative sickle cell retinopathy, including improved visual and anatomic outcomes.

Posted: 5/12/2025

Keywords:

retina-meeting-recap

•

proliferative sickle cell retinopathy

•

Sickle Cell

•

Retinopathy

•

Vitreoretinal Surgery

Up Next

Dosing Considerations with 8 mg Aflibercept

Dosing Considerations with 8 mg Aflibercept

Mark R. Barakat, MD

Pegcetacoplan in the Real World: Year 1

Pegcetacoplan in the Real World: Year 1

Mengxi Shen, MD, PhD

Phase 2a Data Revealed for AVD-104 (Aviceda)

Phase 2a Data Revealed for AVD-104 (Aviceda)

Baruch D. Kuppermann, MD, PhD

Real-World Data for 8 mg Aflibercept

Real-World Data for 8 mg Aflibercept

Vasileios Konidaris, MD, PhD

$The Benefits of Refractive Vitrectomy for SVOs$

The Benefits of Refractive Vitrectomy for SVOs

Paulo Eduardo Stanga, MD

Bariatric Surgery Versus GLP-1 Receptor Agonists

Bariatric Surgery Versus GLP-1 Receptor Agonists

Christabel Chan, MD

Treating DR with Axitinib

Treating DR with Axitinib

Neal S. Shah, MD

Phase 2 Data on Gene Therapy for AMD

Phase 2 Data on Gene Therapy for AMD

Christine Kay, MD

OCS-01 (Oculis) in DME: A Phase 3 Update

OCS-01 (Oculis) in DME: A Phase 3 Update

Carl Danzig, MD

Gene Therapy for Wet AMD: New Phase 2 Data

Gene Therapy for Wet AMD: New Phase 2 Data

Dante Pieramici MD

Back to All Videos

Surgical Pearls for Sickle Cell Retinopathy

Jennifer I. Lim, MD

Dr. Lim explores the benefits of surgical intervention for proliferative sickle cell retinopathy, including improved visual and anatomic outcomes.

Posted: 5/12/2025

Keywords:

retina-meeting-recap

•

proliferative sickle cell retinopathy

•

Sickle Cell

•

Retinopathy

•

Vitreoretinal Surgery

Please log in to leave a comment.

More From ARVO: 2025 Coverage

Phase 2a Data Revealed for AVD-104 (Aviceda)

Phase 2a Data Revealed for AVD-104 (Aviceda)

Baruch D. Kuppermann, MD, PhD

Real-World Data for 8 mg Aflibercept

Real-World Data for 8 mg Aflibercept

Vasileios Konidaris, MD, PhD

$The Benefits of Refractive Vitrectomy for SVOs$

The Benefits of Refractive Vitrectomy for SVOs

Paulo Eduardo Stanga, MD

Bariatric Surgery Versus GLP-1 Receptor Agonists

Bariatric Surgery Versus GLP-1 Receptor Agonists

Christabel Chan, MD

Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of ARVO: 2025.